Tag: Diabetes: Drugs
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
Authors say large, multisite study should provide reassurance for short-term risk
Once-Weekly Efsitora Noninferior to Degludec for Type 2 Diabetes
Once-weekly efsitora noninferior to once-daily degludec for decrease in mean glycated hemoglobin level
Risk for Dementia Similar With SGLT2 Inhibitors, Dulaglutide in T2DM
Estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 versus dulaglutide among older adults
Long-Term Sulfonylurea Use Tied to Impaired Awareness of Hypoglycemia
Odds are lessened with regular diabetes-related medical care
ACP: Recommendations Developed for Newer Type 2 Diabetes Medications
Strong recommendation given for addition of SGLT-2 or GLP-1 agonist to metformin and lifestyle modifications
More Americans Will Only Have to Pay $35 a Month for Insulin in 2024
Metformin Does Not Improve Survival in High-Risk Breast Cancer
Incidence rate of invasive disease-free survival events and incidence rates for death did not differ with addition of metformin, placebo
Mounjaro Approved for Blood Glucose Control in Type 2 Diabetes
The once-weekly injection is approved as an addition to diet and exercise
Medication Type for T2DM May Affect Severe COVID-19 Outcomes
Premorbid GLP1-RA use, SGLT2i use associated with lower 60-day mortality compared to premorbid DPP4i use
Study Looks at T2DM, Metformin Use, and Breast Cancer Risk
Links between T2DM with metformin use and breast cancer risk appear to be affected by hormone receptor status
